MSD
MSD acquires Pandion Therapeutics in $1.85bn deal
February 26, 2021Medical Communications MSD, Pandion
MSD, known as Merck in the United States and Canada, has announced that it will acquire clinical-stage biotechnology company Pandion …
AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival
February 17, 2021Research and Development AstraZeneca, Cancer, MSD
The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …
NICE recommends MSD’s Keytruda in combination with chemotherapy for lung cancer
February 4, 2021Cancer, MSD
NICE has recommended MSD’s Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy (pembrolizumab combination) as a first-line option for untreated, metastatic, …
Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds
February 2, 2021Manufacturing and Production Cancer, MSD
A new trial by Merck – known as MSD outside of North America – has found that their lung cancer …
MSD’s cancer therapy KEYTRUDA gets EU approval
January 26, 2021Manufacturing and Production Cancer, MSD
MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …
MSD discontinues development of COVID-19 vaccines
January 26, 2021Manufacturing and Production MSD, Merck
Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …
MSD cashes in on Moderna investment as FDA mulls COVID-19 vaccine approval
December 4, 2020Medical Communications, Sales and Marketing MSD, Moderna
Moderna has wrestled its way to the forefront of the industry amidst the COVID-19 pandemic, becoming one of its most …
NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
October 22, 2020Sales and Marketing MSD, NCIE, NHS, keytruda
NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …
Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer
September 22, 2020Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma
MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …
New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda
New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …
MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn
September 15, 2020Manufacturing and Production, Sales and Marketing MSD, Seattle Genetics, deal, pharma
MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 billion. …
MSD unveils plans for $1.3bn central London research centre
August 19, 2020Manufacturing and Production, Research and Development London, MSD, pharma
MSD has lifted the lid on plans to build a $1.3 billion research centre in central London.The London Discovery Research …
FDA grants fast review for Bayer and MSD’s heart failure drug vericiguat
July 17, 2020Medical Communications Bayer, FDA, MSD
The FDA has granted a fast Priority Review for Bayer and MSD’s heart failure drug vericiguat. This was based on …
European green light for Lynparza in germline BRCA-mutated metastatic pancreatic cancer
July 8, 2020Research and Development, Sales and Marketing AstraZeneca, Cancer, Europe, MSD, lynparza
The European Commission has awarded approval to AstraZeneca and MSD’s Lynparza (olaparib) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer, with …
Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer
June 1, 2020Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza
Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
